Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double-blind Phase III Trial of FOLF(HA)Iri vs FOLFIRI for Second or Third Line Therapy in Irinotecan-naïve Patients With Metastatic Colorectal Cancer

NCT01290783 is registered in ClinicalTrials.gov with Alchemia Oncology as lead sponsor.

NCT NCT01290783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01290783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double-blind Phase III Trial of FOLF(HA)Iri vs FOLFIRI for Second or Third Line Therapy in Irinotecan-naïve Patients With Metastatic Colorectal Cancer
Lead sponsor
Alchemia Oncology
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2011
Completion date
December 31, 2015
Enrollment
390 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer